Trial Profile

Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Filgrastim (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors BioGeneriX; Teva Pharmaceutical Industries

Most Recent Events

18 Nov 2013 According to the Teva Pharmaceuticals media release, the safety of Filgrastim [Granix] was evaluated in this trial and another two phase III trial in patients receiving myelosuppressive chemotherapy.
07 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com